Clinical Trials Browser

Lung Neoplasms × Crizotinib × Clear all

NCT02194738 2026-04-21

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Phase NA Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06563999 2026-04-21

NUMER

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03737994 2026-04-07

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts

Lung Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT02183870 2022-06-16

EUCROSS

Phase 2 Completed

Adenocarcinoma, Lung Neoplasms

NCT02737501 2021-08-20

ALTA-1L

Phase 3 Completed

275 enrolled 23 charts 2 FDA

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

NCT01945021 2021-02-21

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Phase 2 Completed

129 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT02745691 2019-12-13

Psychometric Properties of the EORTC QLQ-LC29

Lung Neoplasms

NCT02511184 2019-07-01

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Phase 1 Terminated

9 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00965731 2015-10-28

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Phase 1 Completed

27 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms